옵션 체인은 다양한 행사가격과 만기일에 대한 Kymera Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kymera Therapeutics에 대한 시장 심리를 평가합니다..

Kymera Therapeutics (NASDAQ:KYMR) 주식, 옵션 체인

Kymera Therapeutics

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Kymera Therapeutics Inc

Oppenheimer analyst Jay Olson upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Perform to Outperform and announces $6 price target.

Upgrades

Price Target

Analyst Ratings

NKTR

Oppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $6 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $4 price target.

PRQR

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

A top White House representative informed crypto leaders this week that the Trump administration is eager to increase <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44258476/bitcoin-reserve-upgrades-crypto-but-paypal-ripple-stablecoins-lag-behind">its Bitcoin reserves</a> as part of a broader financial strategy.
Bo Hines, the Presidential Working Group on Digital Assets lead, shared with attendees of a confidential meeting hosted by the Bitcoin Policy Institute on Tuesday the government's intent to gather substantial Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stocks, <a href="https://decrypt.co/309948/trump-admin-acquire-much-bitcoin-possible-white-house">according </a>to those present.
The session, following a public "Bitcoin for America" gathering, included key industry figures such as Michael Saylor of Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Fred Thiel of Marathon Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), Nathan McCauley of Anchorage Digital, and David Bailey of Bitcoin Magazine, alongside senators Cynthia Lummis (R-Wyo.), Bill Hagerty (R-Tn.) and Bernie Moreno (R-Oh.).
When pressed on the specific amount the government might target, Hines responded with a lighthearted comparison to asking someone how many dollars they'd like, one participant relayed to Decrypt. 
A White House source later verified Hines' statement, noting that any Bitcoin purchases would be conducted without burdening taxpayers, aligning with a cost-neutral policy. 
This approach supports recent statements from senior officials advocating for additional Bitcoin acquisitions—currently around 200,000 BTC from legal confiscations—to enhance a strategic reserve established by Trump's recent directive.
Also Read: <a href="https://www.benzinga.com/news/25/03/44309155/trump-administration-focused-on-real-economy-not-market-swings-says-treasury-secretary-bessent">Trump Administration Focused On Real Economy, Not Market Swings, Says Treasury Secretary Bessent</a>
During the discussion, a question arose about the administration's stance on the Bitcoin Act, a Senate proposal reintroduced by Lummis on Tuesday, which calls for acquiring up to one million BTC, valued at about $80 billion, and legally embedding the reserve. 
Hines reportedly turned to Lummis, seated nearby, and indicated the administration favors legislation to solidify the reserve and will work to ensure its approval in Congress. 
However, a White House representative clarified to Decrypt that Hines did not back any specific bill during the event. 
The proposal's cost-neutral claim is under debate, as it suggests using Federal Reserve funds from revaluing gold certificates—last updated in 1971 and now worth over 6,800% more due to gold's rise—to finance the purchases.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44304170/trump-family-in-talks-to-acquire-stake-in-binance-as-former-ceo-changpeng-zhao-pushes-for-pardon">Trump Family In Talks To Acquire Stake In Binance As Former CEO Changpeng Zhao Pushes For Pardon</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MARA

MSTR

Trump Administration Signals Aggressive Cost-Neutral Bitcoin Accumulation Strategy

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

Reiteration

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst David George upgraded the rating for American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from Underperform to Neutral and maintained the price target of $265. American Express shares closed at $256.43 on Thursday. <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) from Outperform to Strong Buy but lowered the price target from $128 to $122. Crown Castle shares closed at $95.09 on Thursday. <a href="https://www.benzinga.com/quote/CCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Susan Anderson upgraded Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Buy and announced a $10 price target. Peloton Interactive shares closed at $6.07 on Thursday. <a href="https://www.benzinga.com/quote/PTON/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Hold to Buy and announced a $30 price target. Revolve shares closed at $21.26 on Thursday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Alton Stump upgraded the rating for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Hold to Buy and raised the price target from $58 to $65. Chipotle shares closed at $48.73 on Thursday. <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AXP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-1024x596.png" alt="" class="wp-image-824716" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44324575/top-3-industrials-stocks-that-may-rocket-higher-this-month">Top 3 Industrials Stocks That May Rocket Higher This Month</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

PTON

RVLV

This American Express Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) reported fiscal fourth-quarter 2024 revenue growth of 6.1% year-on-year to 44.3 billion Chinese yuan ($6.07 billion), missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44323458/li-auto-inc-announces-unaudited-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">analyst consensus of 44.6 billion Chinese yuan</a>.&nbsp;
Its adjusted net earnings per ADS&nbsp;were&nbsp;3.79 Chinese yuan ($0.52), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus of 2.87 Chinese yuan</a>. The stock price fell after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44306214/gm-and-pge-team-up-to-let-evs-power-homes-offer-up-to-4500-in-energy-incentives" rel="noreferrer noopener">GM And PG&amp;E Team Up To Let EVs Power Homes, Offer Up To $4,500 In Energy Incentives</a>
Vehicle sales increased 5.6% to $5.8 billion&nbsp;due&nbsp;to increased vehicle deliveries partially offset by the lower average selling price, mainly due to different product mixes. Total vehicle deliveries were 158,696 units in the quarter,&nbsp;a 20.4% year-over-year&nbsp;increase.
The vehicle margin declined by 300 bps&nbsp;year over year&nbsp;to 19.7%, and the gross margin decreased by 320 bps&nbsp;year over year&nbsp;to 20.3%.&nbsp;
Adjusted income from operations&nbsp;was $577.6 million, up by 9.1% Y/Y. Adjusted net income decreased 12.0% Y/Y to $553.4 million.
Li Auto held cash and equivalents of $15.5 billion as of December 31, 2024, and generated $1.2 billion in operating cash flow for the quarter. Free cash flow was $830.1 million.
As of December 31, 2024, the company had 502 retail stores covering 150 cities, 478 servicing centers,&nbsp;Li Auto-authorized body and paint shops operating in 225 cities, and 1,727&nbsp;supercharging&nbsp;stations with 9,100 charging stalls.
Chair and CEO Xiang Li noted the fourth quarter propelled its full-year deliveries to surpass the 500,000 milestone, making it a leading premium automotive brand in China. Looking ahead to 2025, it plans to launch its next-generation autonomous driving architecture and new BEV models.
Q1 Outlook: Li Auto expects quarterly revenue of 23.4 billion Chinese yuan ($3.2 billion)-24.7 billion Chinese yuan ($3.4 billion), representing a <a href="https://www.benzinga.com/calendars/guidance">decrease of 8.7%–3.5% year over year.</a>
LI expects quarterly vehicle deliveries of 88,000-93,000, representing an increase of 9.5%–15.7%&nbsp;year over year.
Price Action: LI stock is down by 3.93% at $27.59 in premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44305045/archer-taps-palantirs-ai-to-supercharge-electric-aircraft-production-and-flight-tech" target="_blank" rel="noreferrer noopener">Archer Taps Palantir&#8217;s AI to Supercharge Electric Aircraft Production and Flight Tech</a></li>
</ul>
Photo by Postmodern Studio on Shutterstock.

Earnings

Guidance

Li Auto Tops 500K Deliveries In 2024, Sees Q1 Slowdown

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Buy and maintains $81 price target.

ARVN

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and lowers the price target from $175 to $168.

NVDA

Mizuho Maintains Outperform on NVIDIA, Lowers Price Target to $168

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/13/final-trades-visa-blackstone-eli-lilly-and-invitation-homes.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington of Requisite Capital Management said she loves Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and recommends buying the <a href="https://www.benzinga.com/quote/V/analyst-ratings">stock on the dip</a>.
The banking behemoth, on March 11, launched a new initiative aimed at tackling complex scams and preventing massive financial losses, per recent news. The company's newly formalized scam disruption practice, under its Visa Payment Ecosystem Risk and Control division, prevented over $350 million in attempted <a href="https://www.benzinga.com/25/03/44255550/whats-going-on-with-visa-stock-today">fraud in 2024 alone</a>.
Jason Snipe of Odyssey Capital Advisors said he likes Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), which is down 20% year-to-date.
On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm&#8217;s AI Transformation initiatives – was named Global Head of Portfolio Operations.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson of Capital Wealth Planning said Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has dominated the pharma space and momentum is not slowing down beyond weight loss as it has got a pipeline of Alzheimer's, oncology and autoimmune.
On March 7, Eli Lilly released new results from Ebglyss's (lebrikizumab-lbkz) long-term study, ADjoin. New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years.
Joshua Brown of Ritholtz Wealth Management named Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) as his final trade.
Supporting his view, Mizuho analyst Haendel St. Juste, on March 13, upgraded the rating for Invitation Homes from Neutral to Outperform and increased the price target from $33 to $36.
Price Action:
<ul>
<li>Visa shares fell 1.3% to close at $328.55 on Thursday.</li>
<li>Blackstone fell 2.9% to settle at $136.53 during Thursday's session.</li>
<li>Eli Lilly declined 2.5% to close at $801.65 on Thursday.</li>
<li>Invitation Homes shares fell 0.6% to close at $32.89 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

INVH

Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

Mizuho analyst Vijay Rakesh maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and lowers the price target from $140 to $120.

Mizuho Maintains Outperform on Advanced Micro Devices, Lowers Price Target to $120

Barrington Research analyst Alexander Paris maintains Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) with a Outperform and maintains $140 price target.

Barrington Research Maintains Outperform on Stride, Maintains $140 Price Target

Loop Capital analyst Alton Stump upgrades Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Hold to Buy and raises the price target from $58 to $65.

Loop Capital Upgrades Chipotle Mexican Grill to Buy, Raises Price Target to $65

WestPark Capital analyst Casey Ryan reiterates WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) with a Buy and maintains $2.61 price target.

MAPS

WestPark Capital Reiterates Buy on WM Tech, Maintains $2.61 Price Target

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round,</a>&#8220; Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nuclear as its Chief Technology Officer and Head of <a href="https://www.benzinga.com/quote/NNE/news">Reactor Development</a>.
Cramer said Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is a &#8220;challenged&#8221; company, and he doesn't really care for it.
RBC Capital analyst Conor McNamara, on March 12, maintained Illumina with an Outperform and lowered the price target from $247 to $128.
When asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), he said, &#8220;Keep looking but do not press the button.&#8221;
As per the recent news, Archer Aviation and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), on March 13, collaborated to build the AI foundation for the future of advanced aviation technologies.
The Mad Money host said he has always liked STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) and recommended buying the stock. &#8220;I think it's just a strong company,&#8221; he added.
Supporting his view, Stephens &amp; Co. analyst Jacob Johnson, on Feb. 6, reiterated Steris with an Overweight rating and maintained a $240 price target.
Cramer said he doesn't know what Sixth Street Specialty Lending, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) really owns, so therefore he can't give his opinion on it.
RBC Capital analyst Kenneth Lee, on Feb. 26, maintained Sixth Street Specialty with an Outperform rating and raised the price target from $23 to $25.
Cramer said he likes Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) very much and recommended to own the stock.
Adding support to his choice, Susquehanna analyst Mehdi Hosseini, on Feb. 20, upgraded Lam Research from Neutral to Positive and raised the price target from $75 to $125.
Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has been an &#8220;amazing stock for many years,&#8221; Cramer said. He recommended buying the stock.
Supporting his view, UBS analyst David Vogt, on March 5, upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
<ul>
<li>Illumina shares fell 0.2% to settle at $84.05 on Thursday.</li>
<li>Archer Aviation shares dipped 3.1% to close at $7.25 during the session.</li>
<li>NANO Nuclear Energy shares gained 1.9% to settle at $28.32.</li>
<li>Steris shares fell 0.9% to close at $222.45.</li>
<li>Sixth Street Specialty Lending shares fell 0.9% to close at $21.96 on Thursday.</li>
<li>Lam Research shares fell 1.7% to settle at $75.26.</li>
<li>Arista Networks shares fell 0.1% to close at $80.14 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Image: Shutterstock

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock

HC Wainwright &amp; Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $10 to $12.

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12

Morgan Stanley analyst Matthew Harrison maintains 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) with a Equal-Weight and lowers the price target from $6 to $5.

TSVT

Morgan Stanley Maintains Equal-Weight on 2seventy bio, Lowers Price Target to $5

Tigress Financial analyst Ivan Feinseth maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Buy and raises the price target from $195 to $200.

ABNB

Tigress Financial Maintains Buy on Airbnb, Raises Price Target to $200

Morgan Stanley analyst Judah Frommer maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Overweight and raises the price target from $22 to $24.

RGNX

Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $24

Jefferies analyst Randal Konik upgrades Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Hold to Buy and announces $30 price target.

Comments

Kymera Therapeutics

Kymera Therapeutics (KYMR) 옵션

Kymera Therapeutics (NASDAQ:KYMR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌